[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-405542-105":59,"doc-detail-405542-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","top-advances-of-the-year-cervical-cancer-commentary","Top advances of the year - Cervical cancer - Commentary","","Cervical cancer continues to affect women in the United States and worldwide despite an effective human papillomavirus vaccine and cancer screening programs. For patients who develop advanced and/or recurrent disease, surgery, radiation, and chemotherapy have long been the main treatment options. Recent progress includes pembrolizumab immunotherapy, front-line checkpoint inhibitor combinations with chemotherapy and study with chemoradiation, and FDA-approved tisotumabvedotin antibody–drug conjugates. Racial, ethnic, and socioeconomic inequities in access to care and clinical trials persist, prompting new guidance to broaden trial participation, while prevention through vaccination and screening remains essential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/top-advances-of-the-year-cervical-cancer-commentary/405542/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/top-advances-of-the-year-cervical-cancer-commentary/405542.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What major recent treatments are highlighted for advanced or recurrent cervical cancer?","Question",{"text":112,"@type":113},"The text highlights immunotherapy with pembrolizumab, checkpoint inhibitors combined with chemotherapy or studied with chemoradiation, and FDA approval of the antibody–drug conjugate tisotumabvedotin (TV).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the article describe immunotherapy’s effectiveness compared with traditional chemotherapy?",{"text":117,"@type":113},"It reports an overall response rate of 14.3% for PD-L1–positive tumors with pembrolizumab, exceeding historical response rates of many traditional chemotherapy agents, and notes later confirmation in the EMPOWER-Cervical trial.",{"name":119,"@type":110,"acceptedAnswer":120},"Why does the article emphasize reducing disparities in cervical cancer care and research?",{"text":121,"@type":113},"Despite new therapies, it states that racial, ethnic, and socioeconomic inequities affect access to care, participation in clinical trials, and survival. It also mentions new FDA guidance requiring more diverse patient inclusion in trials.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},405542,1790903663,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","DOI: 10. 1002/cncr.34617  \nCOMMENTARY  \nTop advances of the year: Cervical cancer  \nSarah E. Podwika MD  | Linda R. Duska MD, MPH   \nDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia School of Medicine, Charlottesville, Virginia, USA  \nCorrespondence  \nSarah E. Podwika, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia School of Medicine, PO Box 800712, Charlottesville, VA 22908‐0812, USA.  \nEmail: [sep4pd@hscmail.mcc.virginia.edu](sep4pd@hscmail.mcc.virginia.edu)  \nAbstract  \nCervical cancer continues to affect women in the United States and throughout the world despite an effective vaccine against human papillomavirus and cancer screening programs. For the women who develop cervical cancer, surgery, radiation, and chemotherapy have been the mainstays of treatment for years. Recently, novel therapeutics have been developed that offer new treatment opportunities for women living with advanced and/or recurrent disease. Immunotherapy has become an important tool against cervical cancer with the approval of pembrolizumab in the second line for advanced or recurrent disease. Checkpoint inhibitors have recently been approved in the front line for advanced and/or recurrent disease in combination with chemotherapy, and they are being studied in the front line in combination with chemoradiation. Antibody–drug conjugates—specifically tisotumabvedotin (TV)—also have recently received Food and Drug Administration (FDA) approval, and TV is currently being studied in combination with checkpoint inhibitors and with carboplatin. Tumor‐infiltrating lymphocytes have been studied in early‐phase trials and have shown promise in small patient series. Despite these new therapies, there continue to be racial, ethnic, and socioeconomic inequities with respect to access to care, access to and participation in clinical trials, and survival in the United States as well as globally. New FDA guidance requires researchers to work to reduce disparities by including women of more diverse backgrounds in clinical trials. Finally, as progress continues to be made in the treatment of established disease, prevention through vaccination and screening remains paramount.  \nPlain language summary  \n􀀏 The treatment of cervical cancer remains a significant problem in the United States and especially worldwide.  \n􀀏 Although early cases can be cured, cervical cancer that has spread remains difficult to treat.  \n􀀏 The past few years have seen significant advances in new therapies and combinations of therapies for women with advanced or recurrent disease.  \n􀀏 Although this is excellent news for these women, cervical cancer is a preventable disease through screening with Papanicolaou smears and vaccination with the human papillomavirus vaccine.  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.  \n© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.  \n􀀏 By improving access to and acceptance of screening and vaccination, we can eradicate cervical cancer in the United States and the world.  \nKEYWORDS  \nantibody–drug conjugate, cervical cancer, disparities, immunotherapy, tumor‐infiltrating lymphocytes  \nINTRODUCTION  \nDespite successful screening modalities and the approval of an effective vaccine, cervical cancer will take the lives of an estimated 4280 women in the United States in 2022.1 Cervical cancer is also the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 20202 (Figure 1). The majority of cases globally occur in middle and lower income countries.3 Moreover, although new diagnoses of cervical cancer in the United States decreased by more th","cbCaicgZJCakG6ci","https://ap.wps.com/l/cbCaicgZJCakG6ci","pdf",561507,"English","# Introduction\n# Immunotherapy\n## PD-1 inhibitor pembrolizumab\n# Antibody–drug conjugates\n# Tumor-infiltrating lymphocytes\n# Disparities in access and clinical trials\n# Prevention and screening","[{\"question\":\"What major recent treatments are highlighted for advanced or recurrent cervical cancer?\",\"answer\":\"The text highlights immunotherapy with pembrolizumab, checkpoint inhibitors combined with chemotherapy or studied with chemoradiation, and FDA approval of the antibody–drug conjugate tisotumabvedotin (TV).\"},{\"question\":\"How does the article describe immunotherapy’s effectiveness compared with traditional chemotherapy?\",\"answer\":\"It reports an overall response rate of 14.3% for PD-L1–positive tumors with pembrolizumab, exceeding historical response rates of many traditional chemotherapy agents, and notes later confirmation in the EMPOWER-Cervical trial.\"},{\"question\":\"Why does the article emphasize reducing disparities in cervical cancer care and research?\",\"answer\":\"Despite new therapies, it states that racial, ethnic, and socioeconomic inequities affect access to care, participation in clinical trials, and survival. It also mentions new FDA guidance requiring more diverse patient inclusion in trials.\"}]","Top advances of the year - Cervical cancer - Commentary | PDF",1790560503,18]